MapLight Therapeutics Financials - Benzinga

MapLight Therapeutics Inc

MPLTNASDAQ

Trade with Public

Trade with Public

$12.60

0.060.48%

At close: Aug 28, 5:00 PM EST

$12.60

N/A

After Hours: 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

MapLight Therapeutics Financials

MapLight Therapeutics (MPLT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
MapLight Therapeutics Q2 EPS $(1.32) Beats $(1.35) Estimate

Benzinga Newsdesk

PRO
MapLight Therapeutics Q1 EPS $(1.34) Misses $(1.11) Estimate

MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(1.34) per share which missed the analyst consensus estimate of $(1.11) by 20.72 percent. This is a 95.43 percent increase over losses of $(29.33) per

Benzinga Newsdesk

Earnings Scheduled For March 26, 2026

Benzinga Insights

PRO
MapLight Therapeutics Q4 EPS $(2.47) Misses $(0.96) Estimate

MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(2.47) per share which missed the analyst consensus estimate of $(0.96) by 156.49 percent. This is a 91.16 percent increase over losses of $(27.95) per

Benzinga Newsdesk

PRO
MapLight Therapeutics Q3 EPS $(37.18) Misses $(1.55) Estimate

MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(37.18) per share which missed the analyst consensus estimate of $(1.55) by 2291 percent. This is a 48.25 percent decrease over losses of $(25.08) per

Benzinga Newsdesk